TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19185399

Group type: EXPERIMENTAL
Intervention: Randomized Clinical Trials (RCTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational Studies
Number of subjects: 0
Study: 17457375

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (gentamicin without NAC)
Number of subjects: 53
Study: 14998473

Group type: EXPERIMENTAL
Intervention: Easyhaler
Number of subjects: 30

Group type: COMPARATOR
Intervention: Accuhaler
Number of subjects: 30

Group type: COMPARATOR
Intervention: Turbuhaler
Number of subjects: 30
Study: 11869770

Group type: EXPERIMENTAL
Intervention: Divalproex sodium (DVPX) monotherapy, mean dose 882 mg qhs, mean level 80.7 mug/ml
Number of subjects: 19
Study: 10437219

Group type: EXPERIMENTAL
Intervention: Qi Lü Tang Decoction for Improving Abnormal Heart Beat
Number of subjects: 84

Group type: COMPARATOR
Intervention: Propafenone (Western drug)
Number of subjects: 84
Study: 7850847

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine (CHX) gel for 5 min/day for 9 days followed by 0.4% stannous fluoride (SnF2) gel for 14 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: 1% chlorhexidine (CHX) gel for 5 min/day for 9 days followed by placebo gel for 14 days
Number of subjects: 19
Study: 3182439

Group type: EXPERIMENTAL
Intervention: Spiramycin (1 g bd for 10 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Doxycycline (200 mg on day 1, then 100 mg once a day from day 2 to day 10)
Number of subjects: 27
Study: 30312595

Group type: EXPERIMENTAL
Intervention: Patient-centered graded exposure intervention added to manual therapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 28383927

Group type: EXPERIMENTAL
Intervention: Expressive writing (writing emotionally about traumatic life events)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Daily activities writing (writing objectively about daily activities)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study: 26034248

Group type: EXPERIMENTAL
Intervention: DULCE intervention (family specialist support until 6-month visit)
Number of subjects: 330
Study: 23497513

Group type: EXPERIMENTAL
Intervention: ICBT plus CBM (cognitive bias modification)
Number of subjects: 128

Group type: COMPARATOR
Intervention: ICBT plus control training
Number of subjects: 128
Study: 21190917

Group type: EXPERIMENTAL
Intervention: Test Clarithromycin tablets 500 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Reference Clarithromycin tablets 500 mg
Number of subjects: 14
Study: 18501094

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy/radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consolidation or maintenance therapy with targeted agents or conventional cytotoxic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation dose escalation using image-guided radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer cytotoxic agents (e.g., pemetrexed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted therapies (e.g., cetuximab, bevacizumab)
Number of subjects: 0
Study: 16131513

Group type: EXPERIMENTAL
Intervention: HIV-infected men with lipoatrophy
Number of subjects: 6

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 6
Study: 14636091

Group type: EXPERIMENTAL
Intervention: 1 hour of bilateral hand-arm vibration at 7.5 Hz and 0.38 cm displacement
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 14
Study: 11000588

Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI) of the septal mitral annulus
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (patients without pseudonormalization)
Number of subjects: 36
Study: 8848912

Group type: EXPERIMENTAL
Intervention: Doxapram 0.5 mg.kg-1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Doxapram 0.5 mg.kg-1 with alfentanil pre-treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 40
Study: 1537485

Group type: EXPERIMENTAL
Intervention: Active electrostimulation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham electrostimulation
Number of subjects: 50
Study: 6376483

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28953856

Group type: EXPERIMENTAL
Intervention: Iron supplementation (0, 1, or 2 mg/kg/day) from 6 weeks to 6 months of age
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Combined supplemented groups (1 or 2 mg/kg/day)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo (0 mg/kg/day)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Iron supplementation (0, 1, or 2 mg/kg/day)
Number of subjects: 285
Study: 27229464

Group type: EXPERIMENTAL
Intervention: SmokeFree Sports intervention
Number of subjects: 961

Group type: COMPARATOR
Intervention: Control group (comparison schools)
Number of subjects: 961
Study: 25595231

Group type: EXPERIMENTAL
Intervention: Classical Test Theory (CTT)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Item Response Theory (IRT)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Rasch Measurement Theory (RMT)
Number of subjects: 240
Study: 23176547

Group type: EXPERIMENTAL
Intervention: 30-week oral language intervention, delivered in three group sessions per week and daily sessions during transition to Reception class
Number of subjects: 180

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 30-week oral language intervention
Number of subjects: 180
Study: 20471545

Group type: EXPERIMENTAL
Intervention: Intravenous paclitaxel and cisplatin
Number of subjects: 0
Study: 18626482

Group type: EXPERIMENTAL
Intervention: Intervention group (environmental changes to promote physical activity)
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 954
Study: 16638440

Group type: EXPERIMENTAL
Intervention: 0.5 percent CAAL
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 1 percent CAAL
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 14529102

Group type: EXPERIMENTAL
Intervention: Roaring Adventures of Puff (RAP) education program
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 162
Study: 11127769

Group type: EXPERIMENTAL
Intervention: Kavosporal forte
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 20
Study: 9167741

Group type: EXPERIMENTAL
Intervention: Cis-platinum (CDDP) 40 mg/m2 weekly with fractionated stereotactic radiotherapy (SRT) once or twice weekly
Number of subjects: 20

Group type: COMPARATOR
Intervention: SRT
Number of subjects: 20
Study: 8396083

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/day once-daily for three days (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Spiramycin 3,000,000 units three-times daily for seven days (n = 30)
Number of subjects: 60
Study: 3543784

Group type: EXPERIMENTAL
Intervention: Anterior subTenon injections (subconjunctival)
Number of subjects: 77015

Group type: COMPARATOR
Intervention: Posterior subTenon injections (retrobulbar)
Number of subjects: 77015
Study: 30643806

Group type: EXPERIMENTAL
Intervention: Arsenic contaminated ground water exposure
Number of subjects: 960
Study: 26342706

Group type: EXPERIMENTAL
Intervention: Dark roasted coffee (DAR)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Light roasted coffee (LIR)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both coffees (LIR and DAR)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Water
Number of subjects: 11
Study: 24885384

Group type: EXPERIMENTAL
Intervention: Oral flucloxacillin for 6 additional days after initial treatment
Number of subjects: 396

Group type: COMPARATOR
Intervention: Placebo for 6 additional days after initial treatment
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Oral flucloxacillin for 6 additional days
Number of subjects: 396
Study: 23279214

Group type: EXPERIMENTAL
Intervention: Aquatic therapy program (3 days/week)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Aquatic therapy program (2 days/week)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 20223672

Group type: EXPERIMENTAL
Intervention: Thalidomide (100mg twice per day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 18484922

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended-release formulation of ropinirole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16338507

Group type: EXPERIMENTAL
Intervention: Albuterol nebulized in heliox
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 41
Study: 14605041

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 20
Study: 11000554

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Amberlite(R) IRP‐69
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Polymer-coated cholestyramine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Polymer-coated IRP‐69
Number of subjects: 4
Study: 8821521

Group type: EXPERIMENTAL
Intervention: Vaginal tablets (Gynoflor) containing 50 mg of Lactobacillus acidophilus and 0.03 mg estriol, administered 1-2 tablets daily for 6 days.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vaginal tablets (Gynoflor)
Number of subjects: 32
Study: 1384919

Group type: EXPERIMENTAL
Intervention: Prazosin (0.5 mg and then 1 mg twice daily for 4 days, then 2 mg twice daily for the remainder of the trial)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 93

Group type: COMPARATOR
Intervention: Prazosin and Placebo
Number of subjects: 93
Study: 3929579

Group type: EXPERIMENTAL
Intervention: TTS-NTG 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: TTS-NTG 20 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30809801

Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention including physical activity, nutritional counseling, vascular risk management, cognitive training, and social activity.
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1260
Study: 30031005

Group type: EXPERIMENTAL
Intervention: Low-Power Holmium laser enucleation of the prostate (LP-HoLEP)
Number of subjects: 121

Group type: COMPARATOR
Intervention: High-Power Holmium laser enucleation of the prostate (HP-HoLEP)
Number of subjects: 121
Study: 27179847

Group type: EXPERIMENTAL
Intervention: Helmet NIV
Number of subjects: 83

Group type: COMPARATOR
Intervention: Face mask NIV
Number of subjects: 83
Study: 24452632

Group type: EXPERIMENTAL
Intervention: Vaginal gels containing antiretroviral drugs
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vaginal gels
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Microbicide acceptability improvements
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Education for users
Number of subjects: 16
Study: 23213953

Group type: EXPERIMENTAL
Intervention: Continuous therapeutic ultrasound on the neck (0.5 w/cm2, five times a day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Programmed isometric exercises specific for the cervical spine and transcutaneous electrical stimulation (TENS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (ultrasound machine switched off)
Number of subjects: 100
Study: 19657359

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 18443399

Group type: EXPERIMENTAL
Intervention: Bipolar cautery tonsillectomy
Number of subjects: 201

Group type: COMPARATOR
Intervention: Classical dissection tonsillectomy
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 201
Study: 19423958

Group type: EXPERIMENTAL
Intervention: Deep inspiration-gated radiation therapy (n=33)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard radiation therapy (n=47)
Number of subjects: 80
Study: 15222838

Group type: EXPERIMENTAL
Intervention: Cohabited before engagement
Number of subjects: 136

Group type: COMPARATOR
Intervention: Cohabited after engagement or at marriage
Number of subjects: 136
Study: 11560567

Group type: EXPERIMENTAL
Intervention: Methionine 15 g
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9677633

Group type: EXPERIMENTAL
Intervention: Terbutaline sulfate nebulization
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (half diluted physiologic serum)
Number of subjects: 28
Study: 8156520

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with cyclophosphamide (4.5-6.0 g/m2), etoposide (750-1500 mg/m2), and cisplatin (120-180 mg/m2) with autologous marrow support
Number of subjects: 76

Group type: COMPARATOR
Intervention: High-dose chemotherapy with cyclophosphamide, etoposide, and cisplatin without autologous marrow support
Number of subjects: 76
Study: 3280114

Group type: EXPERIMENTAL
Intervention: Transfer factor (TF)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 30674084

Group type: EXPERIMENTAL
Intervention: Fat
Number of subjects: 176

Group type: COMPARATOR
Intervention: Gelfoam
Number of subjects: 176
Study: 28238606

Group type: EXPERIMENTAL
Intervention: DXA-VAT
Number of subjects: 1117

Group type: COMPARATOR
Intervention: CT-VAT
Number of subjects: 1117
Study: 26890997

Group type: EXPERIMENTAL
Intervention: Nutrition-Exercise group (GN-Ex, n=10)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nutrition group (GN, n=11)
Number of subjects: 21
Study: 24914630

Group type: EXPERIMENTAL
Intervention: 12 mL mepivacaine 2% (group concentration I)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 24 mL of mepivacaine 1% (group volume II)
Number of subjects: 90
Study: 22732644

Group type: EXPERIMENTAL
Intervention: MOXY fiber (180 watts)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 4090 fiber (120 watts)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 19050607

Group type: EXPERIMENTAL
Intervention: Saline instillation (8 mL of saline before tracheal suctioning)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control (no saline instillation before tracheal suctioning)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Saline instillation
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control
Number of subjects: 262
Study: 17323667

Group type: EXPERIMENTAL
Intervention: AMBU Laryngeal Mask
Number of subjects: 0

Group type: COMPARATOR
Intervention: LMA Classic
Number of subjects: 0
Study: 16136635

Group type: EXPERIMENTAL
Intervention: Ethics consultations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no ethics consultations)
Number of subjects: 0
Study: 11860536

Group type: EXPERIMENTAL
Intervention: Laparoscopic assisted vaginal hysterectomy (LAVH) and bilateral salpingo-oophrectomy (BSO) plus minus laparoscopic pelvic lymphadenectomy (LPLA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH) and BSO plus minus pelvic lymphadenectomy (PLA)
Number of subjects: 61
Study: 10451477

Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil and fish oil supplement (40 g/d of olive oil and 16 g of fish oil for 3 months)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil and fish oil supplement
Number of subjects: 25

Group type: COMPARATOR
Intervention: Refined olive oil (Control group)
Number of subjects: 25
Study: 7561177

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg until bone marrow recovery or initiation of intravenous amphotericin B infusions
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 2193036

Group type: EXPERIMENTAL
Intervention: Sonography
Number of subjects: 68

Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Aspiration under sonographic control
Number of subjects: 68
Study: 646496

Group type: EXPERIMENTAL
Intervention: Truncal vagotomy/antrectomy (TV + A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gastric selective vagotomy/pyloroplasty (GSV + P)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 90
Study: 29514368

Group type: EXPERIMENTAL
Intervention: Two doses of 100 mg hydrocortisone (given 2 hours before and 8 hours after surgery)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Four doses of 100 mg hydrocortisone (8 hours apart)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 103
Study: 27838661

Group type: EXPERIMENTAL
Intervention: ASPIRA web-based, multimedia program
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1369
Study: 25548844

Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA
Number of subjects: 14

Group type: COMPARATOR
Intervention: onabotulinumtoxinA
Number of subjects: 14
Study: 23718573

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss (≥2 kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight gain (≥2 kg)
Number of subjects: 0
Study: 21301358

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii at 2×10^6 live cells daily for 4 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 67
Study: 19587253

Group type: EXPERIMENTAL
Intervention: computer‐based virtual reality intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: no training group
Number of subjects: 102
Study: 17362174

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with sevoflurane anesthesia
Number of subjects: 46

Group type: COMPARATOR
Intervention: Laparotomic surgery with sevoflurane anesthesia
Number of subjects: 46
Study: 14979482

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam 4.5 g three times a day
Number of subjects: 34
Study: 11430967

Group type: EXPERIMENTAL
Intervention: Early feeding (solid food within 8 hours of surgery)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (nothing by mouth for 12-24 hours, then clear liquids, then solid food on the second or third postoperative day)
Number of subjects: 120
Study: 9918416

Group type: EXPERIMENTAL
Intervention: tretinoin 0.1% (T)
Number of subjects: 30

Group type: COMPARATOR
Intervention: tretinoin 0.1% with hydrocortisone 1% (C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo cream (P)
Number of subjects: 30
Study: 8063972

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study: 2840013

Group type: EXPERIMENTAL
Intervention: Fluconazole 25 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluconazole (in vitro, up to 10 micrograms/ml)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketoconazole (in vitro, 0.1 microgram/ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31204604

Group type: EXPERIMENTAL
Intervention: Supportive intervention for family caregivers of patients with cancer
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Person-centered communication
Number of subjects: 63
Study: 28281432

Group type: EXPERIMENTAL
Intervention: Modified World Health Organization surgical safety checklist (MSSCL) implemented in maternity operating theatres
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control arm (no MSSCL implementation)
Number of subjects: 18
Study: 26790257

Group type: EXPERIMENTAL
Intervention: Improved Nuti maneuver
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gufoni maneuver (Control)
Number of subjects: 40
Study: 23739857

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) associated with full-mouth ultrasonic debridement
Number of subjects: 22

Group type: COMPARATOR
Intervention: Full-mouth ultrasonic debridement (Control)
Number of subjects: 22
Study: 21900030

Group type: EXPERIMENTAL
Intervention: Group-based lifestyle counselling (Group A)
Number of subjects: 2738

Group type: COMPARATOR
Intervention: Individual lifestyle counselling (Group B)
Number of subjects: 2738
Study: 19573384

Group type: EXPERIMENTAL
Intervention: IST regimen I (cyclosporine A alone)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: IST regimen II (cyclosporine A and intravenous immunoglobulin)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: IST regimen III (rabbit anti-T-lymphocyte globulin and cyclosporine A)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: IST regimens I, II, and III
Number of subjects: 112
Study: 16637377

Group type: EXPERIMENTAL
Intervention: Oxitocin (10 UI in 2 mL diluted in 18 mL saline solution)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (20 mL saline solution)
Number of subjects: 64
Study: 15500695

Group type: EXPERIMENTAL
Intervention: Mental Health First Aid training
Number of subjects: 753

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 753
Study: 11355937

Group type: EXPERIMENTAL
Intervention: ChlVPP/PABlOE
Number of subjects: 638

Group type: COMPARATOR
Intervention: PABlOE
Number of subjects: 638
Study: 9882081

Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol after antacid (Maalox)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol after high-fat breakfast
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dexketoprofen trometamol in fasting condition
Number of subjects: 24
Study: 8032167

Group type: EXPERIMENTAL
Intervention: Ritanserin (2.5 mg, 5 mg, and 10 mg o.d.)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study: 2689036

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7